Figure 7
ELISpot detection of gag specific immune responses of SIVmac251 infected macaques treated with H-iART/auranofin(AU)/BSO or H-iART/auranofin. PBMCs were stimulated with two separate SIV Gag peptide pools spanning the entire Gag protein sequence. Data are presented as the number of spot forming cells (SFC) per million PBMCs. Panels A,B show the results from macaques treated with H-iART/auranofin/BSO (Panel A: macaque 4890 and Panel B: macaque P157). Panel C shows, as a matter of comparison, the anti-SIV cell-mediated responses of a macaque (P185) that had been treated with H-iART/auranofin without BSO. Numbers of SFC per well were normalized per 106 cells after subtracting the average background (media only) SFC per well. Data were analyzed by repeated-measures ANOVA, followed by the Student-Newman-Keuls post-test. Asterisks mark the statistically significant differences between the baseline levels (during therapy) or those at therapy interruption) and the post-therapy time points: * P < 0.05; ** P < 0.01; *** P < 0.001.